Evaluation of Therapeutic Efficacy and Imaging Capabilities of [sup.153]Sm[sub.2]O[sub.3]-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model

Introduction: Neutron-activated samarium-153-oxide-loaded polystyrene ([[sup.153] Sm]Sm[sub.2] O[sub.3] -PS) microspheres has been developed in previous study as a potential theranostic agent for hepatic radioembolization. In this study, the therapeutic efficacy and diagnostic imaging capabilities o...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-02, Vol.15 (2)
Main Authors: Tan, Hun Yee, Wong, Yin How, Kasbollah, Azahari, Md Shah, Mohammad Nazri, Yahya, Noorazrul, Abdullah, Basri Johan Jeet, Yeong, Chai Hong
Format: Article
Language:English
Subjects:
Care and treatment
Diagnosis
Dosage and administration
Evaluation
Liver cancer
Microspheres
Polystyrene
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Neutron-activated samarium-153-oxide-loaded polystyrene ([[sup.153] Sm]Sm[sub.2] O[sub.3] -PS) microspheres has been developed in previous study as a potential theranostic agent for hepatic radioembolization. In this study, the therapeutic efficacy and diagnostic imaging capabilities of the formulation was assessed using liver cancer Sprague-Dawley (SD) rat model. Methods: Twelve male SD rats (150–200 g) that implanted with N1-S1 hepatoma cell line orthotopically were divided into two groups (study versus control) to monitor the tumour growth along 60 days of treatment. The study group received an intra-tumoural injection of approximately 37 MBq of [[sup.153] Sm]Sm[sub.2] O[sub.3] -PS microspheres, while control group received an intra-tumoural injection of 0.1 mL of saline solution. A clinical single photon emission computed tomography/computed tomography (SPECT/CT) system was used to scan the rats at Day 5 post-injection to investigate the diagnostic imaging capabilities of the microspheres. All rats were monitored for change in tumour volume using a portable ultrasound system throughout the study period. Histopathological examination (HPE) was performed after the rats were euthanized at Day 60. Results: At Day 60, no tumour was observed on the ultrasound images of all rats in the study group. In contrast, the tumour volumes in the control group were 24-fold larger compared to baseline. Statistically significant difference was observed in tumour volumes between the study and control groups (p < 0.05). The SPECT/CT images clearly displayed the location of [[sup.153] Sm]Sm[sub.2] O[sub.3] -PS in the liver tumour of all rats at Day 5 post-injection. Additionally, the [[sup.153] Sm]Sm[sub.2] O[sub.3] -PS microspheres was visible on the CT images and this has added to the benefits of [sup.153] Sm as a CT contrast agent. The HPE results showed that the [[sup.153] Sm]Sm[sub.2] O[sub.3] -PS microspheres remained concentrated at the injection site with no tumour cells observed in the study group. Conclusions: Neutron-activated [[sup.153] Sm]Sm[sub.2] O[sub.3] -PS microspheres demonstrated excellent therapeutic and diagnostic imaging capabilities for theranostic treatment of liver cancer in a SD rat model. Further studies with different animal and tumour models are planned to validate this finding.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15020536